北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 儿科  > 期刊论文
学科主题: 临床医学
题名:
Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension
作者: He, Bing3; Zhang, Fengwen1; Li, Xueying2; Tang, Chaoshu5,6; Lin, Guosheng4; Du, Junbao1; Jin, Hongfang1
关键词: Bosentan ; Iloprost ; Meta-analysis ; Pulmonary arterial hypertension ; Sildenafil
刊名: CIRCULATION JOURNAL
发表日期: 2010-07-01
DOI: 10.1253/circj.CJ-09-0971
卷: 74, 期:7, 页:1458-1464
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Cardiac & Cardiovascular Systems
研究领域[WOS]: Cardiovascular System & Cardiology
关键词[WOS]: INHALED ILOPROST ; DOUBLE-BLIND ; EPOPROSTENOL THERAPY ; BOSENTAN THERAPY ; SILDENAFIL
英文摘要:

Background: The aim of the present meta-analysis was to evaluate the efficacy and safety of treating pulmonary arterial hypertension (PAH) with inhaled iloprost, oral bosentan and sildenafil.

Methods and Results: The randomized controlled trials on the 3 drugs and placebo were retrieved from the databases MEDLINE, EMBASE, BIOSIS Previews and CNKI up to August 2009. In total 11 studies and 1,391 patients were selected. Compared with placebo, iloprost, bosentan and sildenafil reduced clinical worsening significantly (odds ratio [OR]=0.33, 95% confidence interval [CI]=0.22-0.49, P<0.00001), improved New York Heart Association/World Health Organization functional class (OR=2.81, 95%CI=1.95-4.03, P<0.00001), increased the 6-min walk test by 33.19m, reduced systolic pulmonary arterial pressure, mean pulmonary arterial pressure and pulmonary vascular resistance, increased the cardiac index by 0.40 L.min(-1).m(-2) and increased the cardiac output by 0.53 L/min. The incidence of serious adverse events was similar in the medication groups and the placebo group (OR=1.09, 95%CI=0.69-1.71, P=0.72). In terms of the clinical worsening and functional class amelioration, insignificant differences were found among iloprost, bosentan and sildenafil, but iloprost had the highest incidence of serious adverse events among the 3 drugs.

Conclusions: Inhaled iloprost and oral bosentan and sildenafil are effective and safe in treating PAH. (Circ J 2010; 74: 1458-1464)

语种: 英语
WOS记录号: WOS:000279366500032
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/61522
Appears in Collections:北京大学第一临床医学院_儿科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 1, Dept Stat, Beijing 100034, Peoples R China
2.Minist Educ, Key Lab Mol Cardiol, Beijing, Peoples R China
3.Peking Univ, Hosp 1, Dept Pediat, Beijing 100034, Peoples R China
4.Wuhan Univ, Renmin Hosp, Dept Pediat, Wuhan 430072, Peoples R China
5.Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan 430072, Peoples R China
6.Peking Univ, Hlth Sci Ctr, Dept Physiol & Pathophysiol, Beijing 100034, Peoples R China

Recommended Citation:
He, Bing,Zhang, Fengwen,Li, Xueying,et al. Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension[J]. CIRCULATION JOURNAL,2010,74(7):1458-1464.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[He, Bing]'s Articles
[Zhang, Fengwen]'s Articles
[Li, Xueying]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[He, Bing]‘s Articles
[Zhang, Fengwen]‘s Articles
[Li, Xueying]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace